Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
See our semaglutide vs tirzepatide guide and use our semaglutide dosage calculator
Final Verdict The evidence is clear: there is no strong scientific data linking sermorelin to cancer development
THE CLEAN MARKET STANDARD We have carefully selected every single service and wellness essential in our store, ensuring that the services and shop items will balance and optimize the way you feel